Related Experiment Video
Updated: Jan 28, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Lipoprotein(a)-antisense therapy
1Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstraße 1, 80336, Munich, Germany. Anja.Vogt@med.uni-muenchen.de.
Insights
Elevated lipoprotein(a) (Lp(a)) increases cardiovascular disease risk. New antisense oligonucleotide therapies show significant Lp(a) reduction, offering hope for future cardiovascular event prevention.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Elevated lipoprotein(a) (Lp(a)) is a significant risk factor for early and severe cardiovascular disease (CVD).
- Current lipid-modifying therapies, except niacin, do not effectively lower Lp(a), and endpoint trial data is lacking for niacin.
- Lipoprotein apheresis effectively reduces Lp(a) levels and cardiovascular events, but is invasive.
Purpose of the Study:
- To evaluate the efficacy and safety of a novel hepatospecific Apo(a) antisense oligonucleotide (IONIS-APO(a)-LRx) for lowering Lp(a).
- To assess the potential of specific Lp(a) lowering as a therapeutic strategy for cardiovascular risk reduction.
Main Methods:
- Phase 2 clinical trial of IONIS-APO(a)-LRx in patients with elevated Lp(a).
- Administration of varying dosages of the antisense oligonucleotide.
- Monitoring of Lp(a) levels, safety, and tolerability, including injection site reactions.
Main Results:
- High dosages of IONIS-APO(a)-LRx achieved substantial Lp(a) reductions of 72% and 80%.
- Achieved Lp(a) levels below 50 mg/dL in 81% and 98% of participants at highest dosages.
- The drug demonstrated good tolerability and safety, with injection site reactions as the most common side effect.
Conclusions:
- The hepatospecific Apo(a) antisense oligonucleotide IONIS-APO(a)-LRx demonstrates potent and specific Lp(a) lowering capabilities.
- These findings support the potential of this novel therapy for reducing cardiovascular risk in individuals with elevated Lp(a).
- Further Phase 3 trials are anticipated to confirm these results and demonstrate cardiovascular event reduction.
Abstract:
Elevated levels of lipoprotein(a) (Lp(a)) contribute to the risk of early and severe cardiovascular disease (CVD) and Lp(a) is acknowledged as a risk factor to be included in risk assessment. The established lipid-modifying medical therapies do not lower Lp(a) except niacin but no data of endpoint trials are available. Of the new lipid-modifying drugs a few have some impact on Lp(a). Whether the Lp(a) lowering effect contributes to the reduction of CVD events would have to be shown in Lp(a) dedicated trials. None of the available agents is indicated to lower Lp(a). Lipoprotein apheresis lowers levels of Lp(a) significantly by >60% per treatment. Trial data and data of the German Lipoprotein Apheresis Registry show that regular apheresis reduces cardiovascular events. The Apo(a) antisense oligonucleotide is the only approach to specifically lower Lp(a). The IONIS-APO(a)Rx phase 1 and 2 trials showed very substantial decreases of Lp(a) and good tolerability. The hepatospecific variant IONIS-APO(a)-LRx is 30 times more potent. The results of the IONIS-APO(a)-LRx phase 2 trial were presented recently. The highest dosages reduced Lp(a) by 72 and 80%; in about 81 and 98% Lp(a) levels <50 mg/dl were achieved. Tolerability and safety were confirmed, whereby injection site reactions were the most common side effects. This raises hope that the planned phase 3 trial will reproduce these findings and show a reduction of cardiovascular events.
Related Concept Videos
Gene Therapy
Group Therapy
Psychodynamic Therapy
Humanistic Therapy
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Couples Therapy
Core Principles and Techniques
Couples therapy often incorporates cognitive-behavioral principles to identify and modify negative...

